Publications by authors named "Robert Atcher"

Claim this Profile
A
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.
Mehran Makvandi, Edouard Dupis, Jonathan W Engle, F Meiring Nortier, Michael E Fassbender, Robert W Atcher

Target Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved safety and efficacy of Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine.
Ho Sze Chan, Mark W Konijnenberg, Tamara Daniels, Monique Nysus, Mehran Makvandi, Robert W Atcher

EJNMMI Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Preliminary Biological Evaluations of Fluorescent or Promethium Labeled Trastuzumab-Polyethylenimine.
Jonathan Fitzsimmons, Tapan Nayak, Cathy Cutler, Robert Atcher

Biomedicines· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents.
Tapan K Nayak, Megan K Dennis, Chinnasamy Ramesh, Ritwik Burai, Robert W Atcher

ACS Chem Biol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing the unmanageable.
Robert W Atcher

Lancet Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical radioisotopes--what steps can we take to ensure a secure supply?
Robert W Atcher

J Nucl Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensuring the future of nuclear medicine and molecular imaging.
Robert W Atcher

J Nucl Med· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
Tapan K Nayak, Robert W Atcher, Eric R Prossnitz, Jeffrey P Norenberg

Nucl Med Biol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Session 4: strategies for getting the word out.
Robert Atcher

J Nucl Med· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Tapan K Nayak, Jeffrey P Norenberg, Tamara L Anderson, Eric R Prossnitz, Michael G Stabin, Robert W Atcher

Nucl Med Biol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Fu-Min Su, Paul Beaumier, Don Axworthy, Robert Atcher, Alan Fritzberg

Nucl Med Biol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Tapan Nayak, Jeffrey Norenberg, Tamara Anderson, Robert Atcher

Cancer Biother Radiopharm· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis